Citi raised the firm’s price target on Arvinas to $77 from $72 and keeps a Buy rating on the shares. The analyst updated biotechnology models post the Q4 results.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ARVN:
- Arvinas to Participate in Upcoming Investor Conferences
- Arvinas remains one of the best biotechs to own, says Capital One
- Arvinas expects cash to fund requirements into 2026
- Arvinas reports Q4 EPS ($1.56), consensus ($1.22)
- Arvinas Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update